Hazlett, Burt & Watson’s Regeneron Pharmaceuticals REGN Stock Holding History

Hazlett, Burt & Watson’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9K	Hold	14	–	–	﹤0.01%	716
2026 Q1	$11K	Buy	+14	New	+$10.7K	﹤0.01%	683
2025 Q4	–	Sell	-18	Closed	-$10K	–	952
2025 Q3	$10K	Buy	18 +4	+29%	+$2.26K	﹤0.01%	668
2025 Q2	$7K	Hold	14	–	–	﹤0.01%	639
2025 Q1	$9K	Hold	14	–	–	﹤0.01%	590
2024 Q4	$10K	Hold	14	–	–	﹤0.01%	543
2024 Q3	$15K	Hold	14	–	–	0.01%	492
2024 Q2	$15K	Sell	14 -16	-53%	-$15.5K	0.01%	480
2024 Q1	$29K	Hold	30	–	–	0.02%	394
2023 Q4	$26K	Hold	30	–	–	0.02%	385
2023 Q3	$25K	Hold	30	–	–	0.02%	386
2023 Q2	$22K	Hold	30	–	–	0.02%	404
2023 Q1	$25K	Hold	30	–	–	0.02%	362
2022 Q4	$22K	Hold	30	–	–	0.02%	377
2022 Q3	$21K	Hold	30	–	–	0.02%	370
2022 Q2	$18K	Hold	30	–	–	0.02%	394
2022 Q1	$21K	Buy	+30	New	+$19K	0.02%	390

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Hazlett, Burt & Watson's REGN Position: Q2 2026 in Review

Hazlett, Burt & Watson held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 14 shares worth $9K. The position accounts for ﹤0.01% of the portfolio, ranked #716.

Hazlett, Burt & Watson first reported a position in REGN in Q1 2022 and has held it in 17 quarters since. The position peaked at $29K in Q1 2024. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Hazlett, Burt & Watson held 14 shares of Regeneron Pharmaceuticals worth $9K as of Q2 2026.
Hazlett, Burt & Watson left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
Regeneron Pharmaceuticals made up ﹤0.01% of Hazlett, Burt & Watson's portfolio in Q2 2026, its #716 holding.
Hazlett, Burt & Watson first reported a position in Regeneron Pharmaceuticals in Q1 2022 and has held it in 17 quarters since.
Hazlett, Burt & Watson's Regeneron Pharmaceuticals position peaked at $29K in Q1 2024.
1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Hazlett, Burt & Watson's 13F filing for Q2 2026, filed 30 Jul 2026.